Compounds > 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one
Page last updated: 2024-08-26

7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one and Diabetic Neuropathies

7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one has been researched along with Diabetic Neuropathies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Courteix, C; Eschalier, A; Lavarenne, J1

Other Studies

1 other study(ies) available for 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one and Diabetic Neuropathies

ArticleYear
RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats.
    European journal of pharmacology, 1993, Sep-14, Volume: 241, Issue:2-3

    Topics: Analgesics; Analysis of Variance; Animals; Diabetic Neuropathies; Hyperalgesia; Indoles; Isoindoles; Male; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Stereoisomerism; Substance P

1993